Latest Daiichi Sankyo Inc. Stories
SAN DIEGO and PARSIPPANY, N.J., Dec.
JUPITER, Fla. and PARSIPPANY, N.J., Nov.
- Committee votes 9 to 1 to recommend approval of once-daily SAVAYSA for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF) TOKYO,
BOSTON, Oct. 22, 2014 /PRNewswire-USNewswire/ -- The Center for Connected Health today announced a co-development agreement with Daiichi Sankyo, Inc.
- Findings show risk of bleeding, along with overall efficacy(1), consistently ranked among top considerations for cardiologists when choosing a treatment to reduce the risk of stroke in patients with
Daiichi Sankyo and Charleston Laboratories will collaborate on development and commercialization; Charleston will supply all products and retain an option to co-promote in the United States
PARSIPPANY, N.J., April 18, 2014 /PRNewswire/ -- Daiichi Sankyo, Inc.
- The act of sweetening by admixture of some saccharine substance.